biology

Mosunetuzumab

Mosunetuzumab is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Mosunetuzumab rather than just read about it. In short: Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. It bispecifically binds CD20 and CD3 to engage T-cells.

Key takeaways

Mosunetuzumab belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Mosunetuzumab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Mosunetuzumab from memory before moving on to harder problems.

Reference excerpt

Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. It bispecifically binds CD20 and CD3 to engage T-cells. It was developed by Genentech. The most common adverse reactions (≥20%) include cytokine release syndrome, fatigue, rash, pyrexia, and headache. The most common grade 3 to 4 laboratory abnormalities (≥10%) include decreased lymphocyte count, decreased phosphate, increased glucose, decreased neutrophil count, increased uric acid, decreased white blood cell count, decreased hemoglobin, and decreased platelets. Mosunetuzumab was approved for medical use in the European Union in June 2022, and in the United States in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses Mosunetuzumab is indicated for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Contraindications The prescribing information for mosunetuzumab in the US has a boxed warning for serious or life-threatening cytokine release syndrome.

History Mosunetuzumab-axgb was evaluated in GO29781 (NCT02500407), an open-label, multicenter, multi-cohort study. The efficacy population consisted of 90 patients with relapsed or refractory FL who had received at least two prior lines of systemic therapy, including an anti-CD20 monoclonal antibody and an alkylating agent. The US Food and Drug Administration (FDA) granted the application for mosunetuzumab priority review, breakthrough therapy, and orphan drug designations.

Society and culture

Legal status In April 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for mosunetuzumab under the brand name Lunsumio, intended for the treatment of relapsed or refractory follicular lymphoma. The applicant for this medicinal product is Roche Registration GmbH. Mosunetuzumab was approved for medical use in the European Union in June 2022.

Names Mosunetuzumab is the international nonproprietary name (INN).

Withdrawal from Swiss Market In July 2025, Roche withdrew Lunsumio from the Swiss market following failed price negotiations with the Swiss Federal Office of Public Health (BAG). The drug had been available since February 2023 through a special "Early Access" program that allowed reimbursement before complete clinical data was available. Under this arrangement, Roche initially covered treatment costs until efficacy was demonstrated, after which the remaining therapy could exceed 100,000 Swiss francs. When Swissmedic extended the temporary authorization in February 2025 due to still-missing clinical data, Roche rejected the previously negotiated pricing model and demanded higher prices. The BAG refused to modify the agreement, citing concerns that exceptions would set a precedent for other pharmaceutical companies. The withdrawal was announced to oncologists on July 1, 2025, with Roche also refusing to provide individual case reimbursements—a standard Swiss mechanism for exceptional medical situations. Instead, the company offered to provide the medication free through its patient access program for hardship cases. Oncologists criticized the decision as unprecedented, while some experts suggested the withdrawal reflected broader pressures from potential U.S. pricing reforms that could affect Roche's largest market.

References

Worked examples

Example 1 — a first encounter with Mosunetuzumab

Start with the simplest possible case. Write down what Mosunetuzumab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Mosunetuzumab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Mosunetuzumab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Mosunetuzumab

In research: Mosunetuzumab appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Mosunetuzumab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Mosunetuzumab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Drugs developed by Genentech, Monoclonal antibodies for tumors, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Mosunetuzumab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Mosunetuzumab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Mosunetuzumab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Mosunetuzumab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Mosunetuzumab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Mosunetuzumab in simple terms?

Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. It bispecifically binds CD20 and CD3 to engage T-cells.

Why does Mosunetuzumab matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Mosunetuzumab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Mosunetuzumab.